Syndax Pharmaceuticals Inc (SNDX) FinancialsSNDXFinancialSyndax Pharmaceuticals Inc

Evaluating the bottom line, Syndax Pharmaceuticals, Inc. maintains a gross margin of 95.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.95%, while the net margin is -67.82%. These profitability ratios, combined with a Return on Equity (ROE) of -255.93%, provide a clear picture of how effectively SNDX converts its operational activities into shareholder value.

In the context of the broader market, SNDX competes directly with industry leaders such as RXRX and NTLA. With a market capitalization of $1.77B, it holds a significant position in the sector. When comparing efficiency, SNDX's gross margin of 95.59% stands against RXRX's -49.82% and NTLA's 100.00%. Such benchmarking helps identify whether Syndax Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Syndax reported total revenues of $72.8 million for Q2 2026, a 92% increase year-over-year, but still missed expectations by $6.33 million. The gross margin remains strong at around 95.59%, indicating effective cost management despite ongoing losses.